![[bAla8]-Neurokinin A(4-10)](/upload/1124/V33536.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Neurokinin 2 (NK2) receptor. [bAla8]-Neurokinin A(4-10) acts as a selective agonist at the NK2 receptor, which is a G-protein coupled receptor. Activation of the NK2 receptor mediates various physiological processes, including smooth muscle contraction, pain perception, and inflammation.
|
|---|---|
| ln Vitro |
[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist. It is a fragment of the larger peptide neurokinin A. As an agonist, it activates the NK2 receptor, mimicking the effects of the endogenous ligand. This makes it a valuable tool for studying the physiological roles of the NK2 receptor in neurotransmission, smooth muscle contraction, and inflammation.
|
| ln Vivo |
No specific in vivo activity data are documented for [bAla8]-Neurokinin A(4-10) in the provided sources. As a research tool, it is primarily used in in vitro assays to study NK2 receptor function. In vivo studies could be conducted to investigate its effects on smooth muscle contraction, pain, or inflammation in animal models.
|
| Enzyme Assay |
In vitro assays for [bAla8]-Neurokinin A(4-10) typically involve measuring its ability to activate the NK2 receptor. Receptor binding assays can be performed using membrane preparations from cells expressing the NK2 receptor, with radiolabeled neurokinin A as a tracer. Functional assays measure the activation of downstream signaling pathways, such as calcium mobilization or cAMP modulation, in cells expressing the receptor.
|
| Cell Assay |
In vitro cell-based assays for [bAla8]-Neurokinin A(4-10) are performed using cell lines that express the NK2 receptor. Cells are treated with the peptide, and receptor activation is measured by detecting intracellular calcium mobilization using fluorescent indicators or by measuring downstream signaling molecules. The compound's potency and efficacy can be determined from concentration-response curves.
|
| Animal Protocol |
In vivo animal studies for [bAla8]-Neurokinin A(4-10) could be conducted to study its effects on smooth muscle contraction, pain perception, or inflammation. The peptide could be administered to rodents, and physiological responses such as changes in blood pressure, airway resistance, or pain behavior could be measured. However, such studies are not documented in the provided sources.
|
| ADME/Pharmacokinetics |
[bAla8]-Neurokinin A(4-10) has a molecular weight of approximately 780.94 and a molecular formula of C35H56N8O10S. It is a white to off-white solid powder. It has a density of 1.265 g/cm3 and a boiling point of 1236.1°C. It should be stored as a powder at -20°C for up to 3 years or in solution at -80°C for up to 6 months.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for [bAla8]-Neurokinin A(4-10) in the provided sources. As a research compound, it is intended for laboratory use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound.
|
| Additional Infomation |
[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist. It is also known as MEN 10210. Its sequence is Asp-Ser-Phe-Val-{Bal}-Leu-Met-NH2. It is a fragment of neurokinin A and belongs to the tachykinin peptide family. It is used in research to study the physiology of the NK2 receptor and its role in pain, inflammation, and smooth muscle function.
|
| Molecular Formula |
C35H56N8O10S
|
|---|---|
| Molecular Weight |
780.931740000001
|
| Exact Mass |
780.384
|
| CAS # |
122063-01-8
|
| PubChem CID |
9987795
|
| Appearance |
White to off-white solid powder
|
| Density |
1.265g/cm3
|
| Boiling Point |
1236.1ºC at 760mmHg
|
| Flash Point |
701.3ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.563
|
| LogP |
1.64
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
54
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CCNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N
|
| InChi Key |
CKNPSJOMUQBPLA-WTWMNNMUSA-N
|
| InChi Code |
InChI=1S/C35H56N8O10S/c1-19(2)15-24(32(50)40-23(30(37)48)12-14-54-5)39-27(45)11-13-38-35(53)29(20(3)4)43-33(51)25(16-21-9-7-6-8-10-21)41-34(52)26(18-44)42-31(49)22(36)17-28(46)47/h6-10,19-20,22-26,29,44H,11-18,36H2,1-5H3,(H2,37,48)(H,38,53)(H,39,45)(H,40,50)(H,41,52)(H,42,49)(H,43,51)(H,46,47)/t22-,23-,24-,25-,26-,29-/m0/s1
|
| Chemical Name |
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[3-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-oxopropyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2805 mL | 6.4026 mL | 12.8052 mL | |
| 5 mM | 0.2561 mL | 1.2805 mL | 2.5610 mL | |
| 10 mM | 0.1281 mL | 0.6403 mL | 1.2805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
